KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Research & Development (2016 - 2025)

AbbVie (ABBV) has disclosed Research & Development for 14 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 61.93% to $2.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 billion, a 28.89% decrease, with the full-year FY2025 number at $9.1 billion, down 28.89% from a year prior.
  • Research & Development was $2.6 billion for Q4 2025 at AbbVie, up from $2.3 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.8 billion in Q4 2024 to a low of $1.5 billion in Q1 2022.
  • A 5-year average of $2.1 billion and a median of $1.9 billion in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 251.53% in 2024, then plummeted 61.93% in 2025.
  • AbbVie's Research & Development stood at $1.8 billion in 2021, then dropped by 2.03% to $1.8 billion in 2022, then rose by 7.65% to $1.9 billion in 2023, then skyrocketed by 251.53% to $6.8 billion in 2024, then tumbled by 61.93% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Research & Development are $2.6 billion (Q4 2025), $2.3 billion (Q3 2025), and $2.1 billion (Q2 2025).